Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Züst R[au]:

Search results

Items: 23

1.

Standardized focus assay protocol for biosafety level four viruses.

Ackermann-Gäumann R, Siegrist D, Züst R, Signer J, Lenz N, Engler O.

J Virol Methods. 2019 Feb;264:51-54. doi: 10.1016/j.jviromet.2018.12.002. Epub 2018 Dec 1.

PMID:
30513365
2.

The Small-Compound Inhibitor K22 Displays Broad Antiviral Activity against Different Members of the Family Flaviviridae and Offers Potential as a Panviral Inhibitor.

García-Nicolás O, V'kovski P, Vielle NJ, Ebert N, Züst R, Portmann J, Stalder H, Gaschen V, Vieyres G, Stoffel M, Schweizer M, Summerfield A, Engler O, Pietschmann T, Todt D, Alves MP, Thiel V, Pfaender S.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01206-18. doi: 10.1128/AAC.01206-18. Print 2018 Nov.

3.

Using a Virion Assembly-Defective Dengue Virus as a Vaccine Approach.

Shan C, Xie X, Zou J, Züst R, Zhang B, Ambrose R, Mackenzie J, Fink K, Shi PY.

J Virol. 2018 Oct 12;92(21). pii: e01002-18. doi: 10.1128/JVI.01002-18. Print 2018 Nov 1.

4.

Characterization of a candidate tetravalent vaccine based on 2'-O-methyltransferase mutants.

Züst R, Li SH, Xie X, Velumani S, Chng M, Toh YX, Zou J, Dong H, Shan C, Pang J, Qin CF, Newell EW, Shi PY, Fink K.

PLoS One. 2018 Jan 3;13(1):e0189262. doi: 10.1371/journal.pone.0189262. eCollection 2018.

5.

Early endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication.

Kindler E, Gil-Cruz C, Spanier J, Li Y, Wilhelm J, Rabouw HH, Züst R, Hwang M, V'kovski P, Stalder H, Marti S, Habjan M, Cervantes-Barragan L, Elliot R, Karl N, Gaughan C, van Kuppeveld FJ, Silverman RH, Keller M, Ludewig B, Bergmann CC, Ziebuhr J, Weiss SR, Kalinke U, Thiel V.

PLoS Pathog. 2017 Feb 3;13(2):e1006195. doi: 10.1371/journal.ppat.1006195. eCollection 2017 Feb.

6.

Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection.

Xu M, Züst R, Toh YX, Pfaff JM, Kahle KM, Davidson E, Doranz BJ, Velumani S, Tukijan F, Wang CI, Fink K.

J Virol. 2016 Nov 28;90(24):11122-11131. Print 2016 Dec 15.

7.

Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines.

Züst R, Toh YX, Valdés I, Cerny D, Heinrich J, Hermida L, Marcos E, Guillén G, Kalinke U, Shi PY, Fink K.

J Virol. 2014 Jul;88(13):7276-85. doi: 10.1128/JVI.03827-13. Epub 2014 Apr 16.

8.

Competitive fitness in coronaviruses is not correlated with size or number of double-membrane vesicles under reduced-temperature growth conditions.

Al-Mulla HM, Turrell L, Smith NM, Payne L, Baliji S, Züst R, Thiel V, Baker SC, Siddell SG, Neuman BW.

MBio. 2014 Apr 1;5(2):e01107-13. doi: 10.1128/mBio.01107-13.

9.

Flavivirus RNA methylation.

Dong H, Fink K, Züst R, Lim SP, Qin CF, Shi PY.

J Gen Virol. 2014 Apr;95(Pt 4):763-78. doi: 10.1099/vir.0.062208-0. Epub 2014 Jan 31. Review.

PMID:
24486628
10.

Dendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunity.

Perez-Shibayama C, Gil-Cruz C, Nussbacher M, Allgäuer E, Cervantes-Barragan L, Züst R, Ludewig B.

PLoS One. 2013 Nov 28;8(11):e81442. doi: 10.1371/journal.pone.0081442. eCollection 2013.

11.

Rational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques.

Züst R, Dong H, Li XF, Chang DC, Zhang B, Balakrishnan T, Toh YX, Jiang T, Li SH, Deng YQ, Ellis BR, Ellis EM, Poidinger M, Zolezzi F, Qin CF, Shi PY, Fink K.

PLoS Pathog. 2013;9(8):e1003521. doi: 10.1371/journal.ppat.1003521. Epub 2013 Aug 1. Erratum in: PLoS Pathog. 2013;9(9). doi:10.1371/annotation/4d0a4eb9-24be-4d26-bef0-c6cdc8824c69.

12.

Cooperation of Th1 and Th17 cells determines transition from autoimmune myocarditis to dilated cardiomyopathy.

Nindl V, Maier R, Ratering D, De Giuli R, Züst R, Thiel V, Scandella E, Di Padova F, Kopf M, Rudin M, Rülicke T, Ludewig B.

Eur J Immunol. 2012 Sep;42(9):2311-21. doi: 10.1002/eji.201142209. Epub 2012 Jul 13.

13.

Reverse genetics of SARS-related coronavirus using vaccinia virus-based recombination.

van den Worm SH, Eriksson KK, Zevenhoven JC, Weber F, Züst R, Kuri T, Dijkman R, Chang G, Siddell SG, Snijder EJ, Thiel V, Davidson AD.

PLoS One. 2012;7(3):e32857. doi: 10.1371/journal.pone.0032857. Epub 2012 Mar 7.

14.

The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors.

Pfefferle S, Schöpf J, Kögl M, Friedel CC, Müller MA, Carbajo-Lozoya J, Stellberger T, von Dall'Armi E, Herzog P, Kallies S, Niemeyer D, Ditt V, Kuri T, Züst R, Pumpor K, Hilgenfeld R, Schwarz F, Zimmer R, Steffen I, Weber F, Thiel V, Herrler G, Thiel HJ, Schwegmann-Wessels C, Pöhlmann S, Haas J, Drosten C, von Brunn A.

PLoS Pathog. 2011 Oct;7(10):e1002331. doi: 10.1371/journal.ppat.1002331. Epub 2011 Oct 27.

15.

The ADP-ribose-1''-monophosphatase domains of severe acute respiratory syndrome coronavirus and human coronavirus 229E mediate resistance to antiviral interferon responses.

Kuri T, Eriksson KK, Putics A, Züst R, Snijder EJ, Davidson AD, Siddell SG, Thiel V, Ziebuhr J, Weber F.

J Gen Virol. 2011 Aug;92(Pt 8):1899-905. doi: 10.1099/vir.0.031856-0. Epub 2011 Apr 27.

PMID:
21525212
16.

Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5.

Züst R, Cervantes-Barragan L, Habjan M, Maier R, Neuman BW, Ziebuhr J, Szretter KJ, Baker SC, Barchet W, Diamond MS, Siddell SG, Ludewig B, Thiel V.

Nat Immunol. 2011 Feb;12(2):137-43. doi: 10.1038/ni.1979. Epub 2011 Jan 9.

17.

2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members.

Daffis S, Szretter KJ, Schriewer J, Li J, Youn S, Errett J, Lin TY, Schneller S, Zust R, Dong H, Thiel V, Sen GC, Fensterl V, Klimstra WB, Pierson TC, Buller RM, Gale M Jr, Shi PY, Diamond MS.

Nature. 2010 Nov 18;468(7322):452-6. doi: 10.1038/nature09489.

18.

Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity.

Cervantes-Barragan L, Züst R, Maier R, Sierro S, Janda J, Levy F, Speiser D, Romero P, Rohrlich PS, Ludewig B, Thiel V.

MBio. 2010 Sep 14;1(4). pii: e00171-10. doi: 10.1128/mBio.00171-10.

19.

A systems immunology approach to plasmacytoid dendritic cell function in cytopathic virus infections.

Bocharov G, Züst R, Cervantes-Barragan L, Luzyanina T, Chiglintsev E, Chereshnev VA, Thiel V, Ludewig B.

PLoS Pathog. 2010 Jul 22;6(7):e1001017. doi: 10.1371/journal.ppat.1001017.

20.

Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection.

Cervantes-Barragán L, Kalinke U, Züst R, König M, Reizis B, López-Macías C, Thiel V, Ludewig B.

J Immunol. 2009 Jan 15;182(2):1099-106.

21.
22.

Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines.

Züst R, Cervantes-Barragán L, Kuri T, Blakqori G, Weber F, Ludewig B, Thiel V.

PLoS Pathog. 2007 Aug 10;3(8):e109.

23.

Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon.

Cervantes-Barragan L, Züst R, Weber F, Spiegel M, Lang KS, Akira S, Thiel V, Ludewig B.

Blood. 2007 Feb 1;109(3):1131-7. Epub 2006 Sep 19.

Supplemental Content

Support Center